Fujifilm Diosynth to establish viral vector manufacturing in Boston

By The Science Advisory Board staff writers

January 5, 2021 -- Contract development and manufacturing organization (CDMO) Fujifilm Diosynth Biotechnologies will establish a new process development and manufacturing facility in Watertown, MA, near Boston, for viral vectors and advanced therapies.

Funded via a $40 million investment by Fujifilm Corporation, the new facility will be the third location for viral vector CDMO services provided by Fujifilm Diosynth Biotechnologies, according to the company. Process development operations are slated to commence in the fall of 2021, with contract manufacturing services for early-phase clinical trials expected to begin at the facility in the fall of 2023.

The facility will house experimental and analytical equipment for viral vector and advanced therapy process development, the firm said.

Fujifilm Diosynth breaks ground on biologics facility
Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization for biologics, viral vaccines, and gene therapies, held a virtual...
Novavax, Fujifilm begin large-scale manufacturing of COVID-19 vaccine
Novavax and Fujifilm Diosynth have signed an agreement covering the bulk manufacture of Novavax's COVID-19 vaccine candidate, NVX-CoV2373, at Fujifilm's...
Fujifilm Diosynth partners with Oxgene for gene therapy
Fujifilm Diosynth Biotechnologies has partnered with Oxgene to deliver gene therapy products with a 25% reduction in production time, the company reported...
Allterum, FujiFilm begin development, scale-up of monoclonal antibodies for leukemia
Allterum Therapeutics has received a $2.9 million product development grant from the Cancer Research and Prevention Institute of Texas to support...

Copyright © 2021 scienceboard.net


Conferences
Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter